0.95
-0.0001(-0.01%)
Currency In USD
| Previous Close | 0.95 |
| Open | 0.96 |
| Day High | 0.96 |
| Day Low | 0.93 |
| 52-Week High | 1.6 |
| 52-Week Low | 0.69 |
| Volume | 30,048 |
| Average Volume | 198,798 |
| Market Cap | 57.32M |
| PE | -0.66 |
| EPS | -1.43 |
| Moving Average 50 Days | 0.94 |
| Moving Average 200 Days | 1.04 |
| Change | -0 |
If you invested $1000 in Kronos Bio, Inc. (KRON) since IPO date, it would be worth $35.09 as of December 26, 2024 at a share price of $0.95. Whereas If you bought $1000 worth of Kronos Bio, Inc. (KRON) shares 3 years ago, it would be worth $63.5 as of December 26, 2024 at a share price of $0.95.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Kronos Bio Announces CEO Transition and Reduction in Force
GlobeNewswire Inc.
Nov 27, 2024 12:30 PM GMT
– Norbert Bischofberger, Ph.D., is stepping down from his role as President & CEO – – Deborah Knobelman, Ph.D., COO & CFO, is named President & Interim CEO – SAN MATEO, Calif. and CAMBRIDGE, Mass., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc.
Kronos Bio Highlights Preclinical Data that Show p300 KAT Inhibitors Reduce Inflammation in an Oral Presentation at ACR Convergence 2024
GlobeNewswire Inc.
Nov 14, 2024 9:02 PM GMT
– Preclinical data demonstrate the ability of p300 KAT inhibition to modulate multiple pro-inflammatory signaling pathways, including antibodies and cytokine production, in ex vivo and in vivo models at well tolerated exposures – SAN MATEO, Calif. an
Kronos Bio to Present Data at the ASH Annual Meeting from p300 KAT Inhibition Program in Multiple Myeloma
GlobeNewswire Inc.
Nov 05, 2024 2:00 PM GMT
– Data demonstrates Kronos Bio's approach to targeting oncogenic transcription factors and the strong relationship between IRF4 and p300 in Multiple Myeloma – – Poster presentation to take place on Monday, December 9, 2024 – SAN MATEO, Calif. and CAM